Key facts
- It has raised $2.5M.
- Notable investors include Draper Associates, Timothy Draper, BSV Ventures, Draper University, 22 Hor Invest — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for QurieGen
- ·The full record, as it builds
Funding rounds
No funding rounds for QurieGen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QurieGen
Developer of a cancer treatment drug designed to comprehend the fundamental cellular mechanisms driving diseases. The company specializes in proprietary methods of mapping cellular responses, single-cell genomics, and data science to build predictive models of disease biology and drug response, enabling clients to identify new drug targets, develop effective therapies, and reduce the time and cost associated with traditional drug discovery and development.
- Sector
- Healthcare
- HQ
- Nijmegen, Netherlands
- Founded
- 2022
- Employees
- 7
- Website
- quriegen.com/
- Ownership
- Privately Held (backing)
QurieGen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QurieGen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QurieGen in its N-PORT filings yet. We sweep new filings monthly.